Compare Ishares Msci Brazil ETF (EWZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Ishares Msci Brazil ETF trades at $42.98 (market cap $10.93B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7× Ishares Msci Brazil ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EWZ | REGN | |
|---|---|---|
Market Cap | $10.93B | $76.40B |
Volume | 45,143,031 | 626,381 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $852.03 |
52-Week Low | $28.79 | $557.73 |
Typical Hold Time | 50 Days | 107 Days |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is bullish based on moving averages but shows overbought signals with RSI readings above 70. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning indicating market anticipation of policy impacts.
The ETF offers diversification from U.S. markets with exposure to Brazilian commodities and financials. Key risks include election volatility and U.S. trade tariffs. Institutional buying and analyst views suggest cautious optimism, but high RSI levels warrant attention for near-term price pressure.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
